Kenai Therapeutics is a technology company.
Kenai Therapeutics has raised $82.0M across 1 funding round.
Kenai Therapeutics has raised $82.0M in total across 1 funding round.
Kenai Therapeutics has raised $82.0M in total across 1 funding round.
Kenai Therapeutics's investors include Cure Ventures, The Column Group.
Kenai Therapeutics is a clinical-stage biotechnology company developing off-the-shelf, allogeneic neuron replacement therapies using induced pluripotent stem cell (iPSC) technology to treat neurological disorders, primarily Parkinson's disease.[1][2][3] Its lead candidate, RNDP-001, targets moderate to moderate-severe idiopathic Parkinson's by replacing lost dopamine neurons for disease-modifying effects, with additional programs like RNDP-002 and RNDP-003 in discovery for inherited subtypes and other conditions.[2][3][4] Founded in 2022 (formerly Ryne Bio), the company has raised $89M total, including an $82M Series A, and serves clinical research, regenerative medicine, and neurological health sectors, showing strong growth via IND preparations, Phase 1/2 trials starting in 2025, and a new San Diego research facility.[1][3][4]
Kenai Therapeutics emerged from stealth in 2024 as a rebranded entity from Ryne Bio, founded in 2022 in Cambridge, Massachusetts, later shifting headquarters to San Diego, California.[1][2][3] Key figures include CEO Nick Manusos, scientific co-founders Dr. Howard Federoff and Dr. Jeffrey Kordower—industry veterans in neuroscience—and board chair Jeff Jonas from Cure Ventures, bringing expertise in CNS disorders and cell therapy.[3] The idea stemmed from leveraging Nobel Prize-winning iPSC platforms for scalable neuron replacement, backed by an exclusive manufacturing partnership with FUJIFILM Cellular Dynamics for cryopreserved production; early momentum came from $82M Series A funding co-led by Alaska Permanent Fund Corporation, The Column Group, and Cure Ventures, enabling preclinical success and IND filing for RNDP-001.[1][2][3]
Kenai rides the wave of regenerative medicine and cell therapy innovation, particularly iPSC-derived neurons for neurodegeneration, amid a Parkinson's market projected to grow due to aging populations and limited symptomatic treatments like levodopa.[1][2][3] Timing aligns with regulatory momentum for allogeneic therapies (e.g., FDA's RMAT designation potential) and manufacturing advances, favoring Kenai's off-the-shelf model over personalized cells.[2] Market forces include rising CNS disorder prevalence and investor interest in curative biotech, as seen in its Series A from specialized funds; Kenai influences the ecosystem by validating iPSC for Parkinson's, potentially accelerating adoption in ALS, Huntington's, and beyond via partnerships like Gateway Labs.[1][3][4]
Kenai is poised for clinical milestones in 2025, including RNDP-001 Phase 1/2 data readouts and IND submissions, leveraging its San Diego hub for expansion into genetic Parkinson's programs.[1][4] Trends like AI-optimized iPSC manufacturing and combo therapies with gene editing will shape its path, amplifying influence as a leader in neuron replacement amid biotech's shift to functional cures. With strong funding and preclinical proof, Kenai could redefine neurological treatment paradigms, building on its stealth-to-clinical momentum for long-term patient impact.[2][3]
Kenai Therapeutics has raised $82.0M across 1 funding round. Most recently, it raised $82.0M Series A in February 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2024 | $82.0M Series A | Cure Ventures, The Column Group |